Ítem
Acceso Abierto

Genómica y transcriptómica comparativa en cepas de Leishmania de Colombia

dc.contributor.advisorPavia Velandia, Paula Ximena
dc.creatorPatiño, Luz H.
dc.creator.degreeDoctor en Ciencias Biomédicas y Biológicasspa
dc.creator.degreetypeFull timespa
dc.date.accessioned2019-10-07T12:32:03Z
dc.date.available2019-10-07T12:32:03Z
dc.date.created2019-09-26
dc.descriptionLa Leishmaniasis es una enfermedad tropical ocasionada por parásitos protozoarios del género Leishmania. En Colombia esta enfermedad representa un grave problema de salud pública debido al elevado número de casos reportados anualmente, la cantidad de especies encontradas y la aparición de cepas resistentes, principalmente frente a los medicamentos de primera línea: antimoniato N-metil glucamina (Glucantime®). Hasta el momento, varios estudios utilizando técnicas de secuenciación de última generación y basados en herramientas como las “omicas” han proporcionado información crucial con respecto a los mecanismos de resistencia y adaptación utilizados por estos parásitos frente a los antimoniales. Sin embargo, este conocimiento en especies de Leishmania del nuevo mundo son escasos, así como estudios que permitan describir la arquitectura genómica intra-especifica en estas especies. Teniendo en cuenta lo anterior, este estudio evaluó el comportamiento genómico y transcriptómico de las principales especies de Leishmania que circulan en Colombia bajo la presión al N-metil glucamina (Glucantime® (SbIII), así como la arquitectura genómica de estas especies, obtenidas a partir de aislamientos clínicos. Los resultados producto de esta tesis permitieron describir que (i) la distribución de las especies de Leishmania a nivel urbano/selvático es diferente, (ii) los cambios genómicos y transcriptómicos en respuesta a los antimoniales trivalentes es una característica compartida entre especies del viejo y del nuevo mundo y (iii) describir la baja variación estructural encontrada en Leishmania braziliensis y Leishmania panamensis. Finalmente, consideramos que estudios adicionales son necesarios con el propósito de seguir ampliando el conocimiento acerca de los mecanismos de adaptación de este parásito.spa
dc.description.abstractLeishmaniasis is a tropical disease caused by protozoan parasites of the genus Leishmania. In Colombia, this disease represents a serious public health problem due to the high number of cases reported annually, the number of species found and the appearance of resistant strains, mainly compared to first-line drugs: N-methyl glucamine antimoniato (Glucantime®) . So far, several studies using next generation sequencing and tools based on “omicas” have provided crucial information regarding the resistance and adaptation mechanisms used by these parasites against antimonials. However, this knowledge in Leishmania species of the new world is scarce, as well as studies that allow to describe the intra-specific genomic architecture in these species. Taking into account the above, this study evaluated the genomic and transcriptomic behavior of the main Leishmania species that circulate in Colombia under the pressure of N-methyl glucamine (Glucantime® (SbIII), as well as the genomic architecture of these species, obtained at from clinical isolates. The results of this thesis allowed us to describe that (i) the distribution of Leishmania species at urban / jungle level is different, (ii) genomic and transcriptomic changes in response to trivalent antimonials is a characteristic shared between species of the old and of the new world and (iii) describe the low structural variation found in Leishmania braziliensis and Leishmania panamensis. Finally, we consider that additional studies are necessary in order to continue expanding the knowledge about the adaptation mechanisms of this parasite. eng
dc.description.sponsorshipDepartamento administrativo de Ciencia, Tecnología e Innovación (Colciencias), dentro del marco del Programa Nacional para promover la formación en la investigación (convocatoria 647)spa
dc.description.sponsorshipDirección Académica de la Universidad del Rosariospa
dc.description.sponsorshipDirección de Investigación e Innovación de la Universidad del Rosariospa
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_20397
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/20397
dc.language.isospaspa
dc.publisherUniversidad del Rosariospa
dc.publisher.departmentFacultad de Ciencias Naturales y Matemáticasspa
dc.publisher.programDoctorado en Ciencias Biomédicas y Biológicasspa
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombiaspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.rights.licenciaPARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe.
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.source.bibliographicCitationHerwaldt BL: Leishmaniasis. Lancet 1999, 354(9185):1191-1199.spa
dc.source.bibliographicCitationFraga J, Veland N, Montalvo AM, Praet N, Boggild AK, Valencia BM, Arevalo J, Llanos-Cuentas A, Dujardin JC, Van der Auwera G: Accurate and rapid species typing from cutaneous and mucocutaneous leishmaniasis lesions of the New World. Diagnostic microbiology and infectious disease 2012, 74(2):142- 150.spa
dc.source.bibliographicCitationMarquis N, Gourbal B, Rosen BP, Mukhopadhyay R, Ouellette M: Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Molecular microbiology 2005, 57(6):1690-1699.spa
dc.source.bibliographicCitationDesjeux P: Leishmaniasis: current situation and new perspectives. Comparative immunology, microbiology and infectious diseases 2004, 27(5):305- 318.spa
dc.source.bibliographicCitationHashiguchi Y, Gomez EL, Kato H, Martini LR, Velez LN, Uezato H: Diffuse and disseminated cutaneous leishmaniasis: clinical cases experienced in Ecuador and a brief review. Tropical medicine and health 2016, 44:2.spa
dc.source.bibliographicCitationReithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S: Cutaneous leishmaniasis. The Lancet Infectious diseases 2007, 7(9):581-596.spa
dc.source.bibliographicCitationvan Griensven J, Diro E: Visceral leishmaniasis. Infectious disease clinics of North America 2012, 26(2):309-322.spa
dc.source.bibliographicCitationRoatt BM, Aguiar-Soares RD, Coura-Vital W, Ker HG, Moreira N, Vitoriano- Souza J, Giunchetti RC, Carneiro CM, Reis AB: Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease. Frontiers in immunology 2014, 5:272.spa
dc.source.bibliographicCitationLukes J, Mauricio IL, Schonian G, Dujardin JC, Soteriadou K, Dedet JP, Kuhls K, Tintaya KW, Jirku M, Chocholova E et al: Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(22):9375-9380.spa
dc.source.bibliographicCitationBanuls AL, Hide M, Prugnolle F: Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Advances in parasitology 2007, 64:1-109.spa
dc.source.bibliographicCitationWorld Health O: Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis. World Health Organization technical report series 2012(975):v-xii, 1-100.spa
dc.source.bibliographicCitationBoaventura VS, Cafe V, Costa J, Oliveira F, Bafica A, Rosato A, de Freitas LA, Brodskyn C, Barral-Netto M, Barral A: Concomitant early mucosal and cutaneous leishmaniasis in Brazil. The American journal of tropical medicine and hygiene 2006, 75(2):267-269.spa
dc.source.bibliographicCitationPassi D, Sharma S, Dutta S, Gupta C: Localised leishmaniasis of oral mucosa: report of an unusual clinicopathological entity. Case reports in dentistry 2014, 2014:753149.spa
dc.source.bibliographicCitationCosta JW, Jr., Milner DA, Jr., Maguire JH: Mucocutaneous leishmaniasis in a US citizen. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 2003, 96(5):573-577.spa
dc.source.bibliographicCitationTorres EM, Sokolsky T, Tucker CM, Chan LY, Boselli M, Dunham MJ, Amon A: Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 2007, 317(5840):916-924.spa
dc.source.bibliographicCitationHernandez C, Alvarez C, Gonzalez C, Ayala MS, Leon CM, Ramirez JD: Identification of six New World Leishmania species through the implementation of a High-Resolution Melting (HRM) genotyping assay. Parasites & vectors 2014, 7:501.spa
dc.source.bibliographicCitationGuerra JA, Prestes SR, Silveira H, Coelho LI, Gama P, Moura A, Amato V, Barbosa M, Ferreira LC: Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PLoS neglected tropical diseases 2011, 5(3):e980.spa
dc.source.bibliographicCitationMedeiros AR, Silva WA, Jr., Roselino AM: DNA sequencing confirms the involvement of Leishmania (L.) amazonensis in American tegumentary leishmaniasis in the state of Sao Paulo, Brazil. Clinics 2008, 63(4):451-456.spa
dc.source.bibliographicCitationOrganización Panamericana de la Salud OMdlS: Manual de procedimientos para vigilancia y control de las leishmaniasis en las Américas. Recuperado de http://iris.paho.org/xmlui/bitstream/handle/123456789/50524/978927532063 1_spa.pdf?sequence=1&isAllowed=y. 2019.spa
dc.source.bibliographicCitationAzmi K, Schonian G, Nasereddin A, Schnur LF, Sawalha S, Hamarsheh O, Ereqat S, Amro A, Qaddomi SE, Abdeen Z: Epidemiological and clinical features of cutaneous leishmaniases in Jenin District, Palestine, including characterisation of the causative agents in clinical samples. Transactions of the Royal Society of Tropical Medicine and Hygiene 2012, 106(9):554-562.spa
dc.source.bibliographicCitationGoto H, Lauletta Lindoso JA: Cutaneous and mucocutaneous leishmaniasis. Infectious disease clinics of North America 2012, 26(2):293-307.spa
dc.source.bibliographicCitationValderrama-Ardila C, Alexander N, Ferro C, Cadena H, Marin D, Holford TR, Munstermann LE, Ocampo CB: Environmental risk factors for the incidence of American cutaneous leishmaniasis in a sub-Andean zone of Colombia (Chaparral, Tolima). The American journal of tropical medicine and hygiene 2010, 82(2):243-250.spa
dc.source.bibliographicCitationRamirez JD, Hernandez C, Leon CM, Ayala MS, Florez C, Gonzalez C: Taxonomy, diversity, temporal and geographical distribution of Cutaneous Leishmaniasis in Colombia: A retrospective study. Scientific reports 2016, 6:28266.spa
dc.source.bibliographicCitationCamara Coelho LI, Paes M, Guerra JA, Barbosa M, Coelho C, Lima B, Brito ME, Brandao Filho SP: Characterization of Leishmania spp. causing cutaneous leishmaniasis in Manaus, Amazonas, Brazil. Parasitology research 2011, 108(3):671-677.spa
dc.source.bibliographicCitationRodriguez-Barraquer I, Gongora R, Prager M, Pacheco R, Montero LM, Navas A, Ferro C, Miranda MC, Saravia NG: Etiologic agent of an epidemic of cutaneous leishmaniasis in Tolima, Colombia. The American journal of tropical medicine and hygiene 2008, 78(2):276-282.spa
dc.source.bibliographicCitationAlvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, Team WHOLC: Leishmaniasis worldwide and global estimates of its incidence. PloS one 2012, 7(5):e35671.spa
dc.source.bibliographicCitationIantorno SA, Durrant C, Khan A, Sanders MJ, Beverley SM, Warren WC, Berriman M, Sacks DL, Cotton JA, Grigg ME: Gene Expression in Leishmania Is Regulated Predominantly by Gene Dosage. mBio 2017, 8(5).spa
dc.source.bibliographicCitationFrieden TR, Centers for Disease C, Prevention: CDC Health Disparities and Inequalities Report - United States, 2013. Foreword. MMWR supplements 2013, 62(3):1-2.spa
dc.source.bibliographicCitationAlmeida LV, Coqueiro-Dos-Santos A, Rodriguez-Luiz GF, McCulloch R, Bartholomeu DC, Reis-Cunha JL: Chromosomal copy number variation analysis by next generation sequencing confirms ploidy stability in Trypanosoma brucei subspecies. Microbial genomics 2018, 4(10).spa
dc.source.bibliographicCitationReis-Cunha JL, Rodrigues-Luiz GF, Valdivia HO, Baptista RP, Mendes TA, de Morais GL, Guedes R, Macedo AM, Bern C, Gilman RH et al: Chromosomal copy number variation reveals differential levels of genomic plasticity in distinct Trypanosoma cruzi strains. BMC genomics 2015, 16:499.spa
dc.source.bibliographicCitationSivigila: Boletin epidemiológico. Sistema Nacional de Vigilancia en Salud Pública -SIVIGILA. 2018.spa
dc.source.bibliographicCitationJariyapan N, Daroontum T, Jaiwong K, Chanmol W, Intakhan N, Sor-Suwan S, Siriyasatien P, Somboon P, Bates MD, Bates PA: Leishmania (Mundinia) orientalis n. sp. (Trypanosomatidae), a parasite from Thailand responsible for localised cutaneous leishmaniasis. Parasites & vectors 2018, 11(1):351.spa
dc.source.bibliographicCitationAkhoundi M, Kuhls K, Cannet A, Votypka J, Marty P, Delaunay P, Sereno D: A Historical Overview of the Classification, Evolution, and Dispersion of Leishmania Parasites and Sandflies. PLoS neglected tropical diseases 2016, 10(3):e0004349.spa
dc.source.bibliographicCitationVan der Auwera G, Dujardin JC: Species typing in dermal leishmaniasis. Clinical microbiology reviews 2015, 28(2):265-294.spa
dc.source.bibliographicCitationBates PA: Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. International journal for parasitology 2007, 37(10):1097-1106.spa
dc.source.bibliographicCitationGangneux JP, Menotti J, Lorenzo F, Sarfati C, Blanche H, Bui H, Pratlong F, Garin YJ, Derouin F: Prospective value of PCR amplification and sequencing for diagnosis and typing of old world Leishmania infections in an area of nonendemicity. Journal of clinical microbiology 2003, 41(4):1419-1422.spa
dc.source.bibliographicCitationArana M, Evans DA, Zolessi A, Cuentas AL, Arevalo J: Biochemical characterization of Leishmania (Viannia) braziliensis and Leishmania (Viannia) peruviana by isoenzyme electrophoresis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1990, 84(4):526-529.spa
dc.source.bibliographicCitationTsukayama P, Lucas C, Bacon DJ: Typing of four genetic loci discriminates among closely related species of New World Leishmania. International journal for parasitology 2009, 39(3):355-362.spa
dc.source.bibliographicCitationReithinger R, Dujardin JC: Molecular diagnosis of leishmaniasis: current status and future applications. Journal of clinical microbiology 2007, 45(1):21- 25.spa
dc.source.bibliographicCitationWeigle KA, Labrada LA, Lozano C, Santrich C, Barker DC: PCR-based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (Viannia). Journal of clinical microbiology 2002, 40(2):601-606.spa
dc.source.bibliographicCitationB SLFdS, Rezende AM, Melo Neto OP, Brito MEF, Brandao Filho SP: Identification of divergent Leishmania (Viannia) braziliensis ecotypes derived from a geographically restricted area through whole genome analysis. PLoS neglected tropical diseases 2019, 13(6):e0007382.spa
dc.source.bibliographicCitationGhouila A, Guerfali FZ, Atri C, Bali A, Attia H, Sghaier RM, Mkannez G, Dickens NJ, Laouini D: Comparative genomics of Tunisian Leishmania major isolates causing human cutaneous leishmaniasis with contrasting clinical severity. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2017, 50:110-120.spa
dc.source.bibliographicCitationSingh S, Sivakumar R: Challenges and new discoveries in the treatment of leishmaniasis. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2004, 10(6):307-315.spa
dc.source.bibliographicCitationdo Monte-Neto RL, Coelho AC, Raymond F, Legare D, Corbeil J, Melo MN, Frezard F, Ouellette M: Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLoS neglected tropical diseases 2011, 5(5):e1167.spa
dc.source.bibliographicCitationHenao HH, Osorio Y, Saravia NG, Gomez A, Travi B: [Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application]. Biomedica : revista del Instituto Nacional de Salud 2004, 24(4):393-402.spa
dc.source.bibliographicCitationFrezard F, Demicheli C, Ribeiro RR: Pentavalent antimonials: new perspectives for old drugs. Molecules 2009, 14(7):2317-2336.spa
dc.source.bibliographicCitationWang H, Xing X, Wang J, Pang B, Liu M, Larios-Valencia J, Liu T, Liu G, Xie S, Hao G et al: Hypermutation-induced in vivo oxidative stress resistance enhances Vibrio cholerae host adaptation. PLoS pathogens 2018, 14(10):e1007413.spa
dc.source.bibliographicCitationDenamur E, Tenaillon O, Deschamps C, Skurnik D, Ronco E, Gaillard JL, Picard B, Branger C, Matic I: Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli. Genetics 2005, 171(2):825-827.spa
dc.source.bibliographicCitationFrezard F, Demicheli C, Ferreira CS, Costa MA: Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate. Antimicrobial agents and chemotherapy 2001, 45(3):913-916.spa
dc.source.bibliographicCitationMookerjee Basu J, Mookerjee A, Sen P, Bhaumik S, Sen P, Banerjee S, Naskar K, Choudhuri SK, Saha B, Raha S et al: Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrobial agents and chemotherapy 2006, 50(5):1788-1797.spa
dc.source.bibliographicCitationWyllie S, Cunningham ML, Fairlamb AH: Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. The Journal of biological chemistry 2004, 279(38):39925-39932.spa
dc.source.bibliographicCitationMoreira W, Leprohon P, Ouellette M: Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell death & disease 2011, 2:e201.spa
dc.source.bibliographicCitationSereno D, Holzmuller P, Mangot I, Cuny G, Ouaissi A, Lemesre JL: Antimonialmediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrobial agents and chemotherapy 2001, 45(7):2064-2069.spa
dc.source.bibliographicCitationMoreira DS, Monte Neto RL, Andrade JM, Santi AM, Reis PG, Frezard F, Murta SM: Molecular characterization of the MRPA transporter and antimony uptake in four New World Leishmania spp. susceptible and resistant to antimony. International journal for parasitology Drugs and drug resistance 2013, 3:143-153.spa
dc.source.bibliographicCitationHaldar AK, Sen P, Roy S: Use of antimony in the treatment of leishmaniasis: current status and future directions. Molecular biology international 2011, 2011:571242.spa
dc.source.bibliographicCitationLeon O, Roth M: Zinc fingers: DNA binding and protein-protein interactions. Biological research 2000, 33(1):21-30.spa
dc.source.bibliographicCitationWebb JR, McMaster WR: Molecular cloning and expression of a Leishmania major gene encoding a single-stranded DNA-binding protein containing nine "CCHC" zinc finger motifs. The Journal of biological chemistry 1993, 268(19):13994-14002.spa
dc.source.bibliographicCitationFrezard F, Monte-Neto R, Reis PG: Antimony transport mechanisms in resistant leishmania parasites. Biophysical reviews 2014, 6(1):119-132.spa
dc.source.bibliographicCitationOuellette M, Drummelsmith J, Papadopoulou B: Leishmaniasis: drugs in the clinic, resistance and new developments. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2004, 7(4- 5):257-266.spa
dc.source.bibliographicCitationSundar S, Singh A: Recent developments and future prospects in the treatment of visceral leishmaniasis. Therapeutic advances in infectious disease 2016, 3(3-4):98-109.spa
dc.source.bibliographicCitationChappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M: Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nature reviews Microbiology 2007, 5(11):873-882.spa
dc.source.bibliographicCitationCroft SL, Olliaro P: Leishmaniasis chemotherapy--challenges and opportunities. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2011, 17(10):1478-1483.spa
dc.source.bibliographicCitationJha SN, Singh NK, Jha TK: Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. The Journal of the Association of Physicians of India 1991, 39(4):314-316.spa
dc.source.bibliographicCitationAmato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC: Mucosal leishmaniasis . Current scenario and prospects for treatment. Acta tropica 2008, 105(1):1-9.spa
dc.source.bibliographicCitationSingh N, Kumar M, Singh RK: Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pacific journal of tropical medicine 2012, 5(6):485-497.spa
dc.source.bibliographicCitationWHO (2010) Control of the Leishmaniasis RoamotWECotCoL.spa
dc.source.bibliographicCitationBray PG, Barrett MP, Ward SA, de Koning HP: Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends in parasitology 2003, 19(5):232-239.spa
dc.source.bibliographicCitationFernandez OL, Diaz-Toro Y, Ovalle C, Valderrama L, Muvdi S, Rodriguez I, Gomez MA, Saravia NG: Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia. PLoS neglected tropical diseases 2014, 8(5):e2871.spa
dc.source.bibliographicCitationDorlo TP, Balasegaram M, Beijnen JH, de Vries PJ: Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. The Journal of antimicrobial chemotherapy 2012, 67(11):2576-2597.spa
dc.source.bibliographicCitationMurray HW: Leishmaniasis in the United States: treatment in 2012. The American journal of tropical medicine and hygiene 2012, 86(3):434-440.spa
dc.source.bibliographicCitationTahir M, Bashir U, Hafeez J, Ghafoor R: Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan. Pakistan journal of medical sciences 2019, 35(2):495-499.spa
dc.source.bibliographicCitationRubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodriguez-Barraquer I, Garcerant D, Prager M, Osorio L, Rojas MX, Perez M et al: Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. The Journal of infectious diseases 2012, 205(4):684-692.spa
dc.source.bibliographicCitationObonaga R, Fernandez OL, Valderrama L, Rubiano LC, Castro Mdel M, Barrera MC, Gomez MA, Gore Saravia N: Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species. Antimicrobial agents and chemotherapy 2014, 58(1):144-152.spa
dc.source.bibliographicCitationSoto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD et al: Miltefosine for new world cutaneous leishmaniasis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004, 38(9):1266-1272.spa
dc.source.bibliographicCitationSundar S: Drug resistance in Indian visceral leishmaniasis. Tropical medicine & international health : TM & IH 2001, 6(11):849-854.spa
dc.source.bibliographicCitationHadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M: Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS medicine 2006, 3(5):e162.spa
dc.source.bibliographicCitationBermudez H, Rojas E, Garcia L, Desjeux P, Dujardin JC, Boelaert M, Chappuis F: Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. Annals of tropical medicine and parasitology 2006, 100(7):591-600.spa
dc.source.bibliographicCitationRomero GA, Guerra MV, Paes MG, Macedo VO: Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. The American journal of tropical medicine and hygiene 2001, 65(5):456-465.spa
dc.source.bibliographicCitationTeixeira AC, Paes MG, Guerra Jde O, Prata A, Silva-Vergara ML: Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Revista do Instituto de Medicina Tropical de Sao Paulo 2008, 50(3):157-160.spa
dc.source.bibliographicCitationTuon FF, Neto VA, Amato VS: Leishmania: origin, evolution and future since the Precambrian. FEMS immunology and medical microbiology 2008, 54(2):158-166.spa
dc.source.bibliographicCitationLlanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda-Verastegui C, Santamaria-Castrellon G, Ramirez L, Lazo M, De Doncker S, Boelaert M, Robays J et al: Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008, 46(2):223-231.spa
dc.source.bibliographicCitationValencia C, Arevalo J, Dujardin JC, Llanos-Cuentas A, Chappuis F, Zimic M: Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions. PLoS neglected tropical diseases 2012, 6(6):e1656.spa
dc.source.bibliographicCitationArevalo J, Ramirez L, Adaui V, Zimic M, Tulliano G, Miranda-Verastegui C, Lazo M, Loayza-Muro R, De Doncker S, Maurer A et al: Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. The Journal of infectious diseases 2007, 195(12):1846-1851.spa
dc.source.bibliographicCitationPalacios R, Osorio LE, Grajalew LF, Ochoa MT: Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. The American journal of tropical medicine and hygiene 2001, 64(3-4):187-193.spa
dc.source.bibliographicCitationRojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG: Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. The Journal of infectious diseases 2006, 193(10):1375- 1383.spa
dc.source.bibliographicCitationPerez-Franco JE, Cruz-Barrera ML, Robayo ML, Lopez MC, Daza CD, Bedoya A, Marino ML, Saavedra CH, Echeverry MC: Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate. PLoS neglected tropical diseases 2016, 10(5):e0004739.spa
dc.source.bibliographicCitationLaffitte MN, Leprohon P, Papadopoulou B, Ouellette M: Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance. F1000Research 2016, 5:2350.spa
dc.source.bibliographicCitationBrotherton MC, Bourassa S, Leprohon P, Legare D, Poirier GG, Droit A, Ouellette M: Proteomic and genomic analyses of antimony resistant Leishmania infantum mutant. PloS one 2013, 8(11):e81899.spa
dc.source.bibliographicCitationMatrangolo FS, Liarte DB, Andrade LC, de Melo MF, Andrade JM, Ferreira RF, Santiago AS, Pirovani CP, Silva-Pereira RA, Murta SM: Comparative proteomic analysis of antimony-resistant and -susceptible Leishmania braziliensis and Leishmania infantum chagasi lines. Molecular and biochemical parasitology 2013, 190(2):63-75.spa
dc.source.bibliographicCitationKaur G, Rajput B: Comparative analysis of the omics technologies used to study antimonial, amphotericin B, and pentamidine resistance in leishmania. Journal of parasitology research 2014, 2014:726328.spa
dc.source.bibliographicCitationDowning T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, Hilley JD, de Doncker S, Maes I, Mottram JC et al: Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome research 2011, 21(12):2143-2156.spa
dc.source.bibliographicCitationRastrojo A, Garcia-Hernandez R, Vargas P, Camacho E, Corvo L, Imamura H, Dujardin JC, Castanys S, Aguado B, Gamarro F et al: Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs. International journal for parasitology Drugs and drug resistance 2018, 8(2):246-264.spa
dc.source.bibliographicCitationValdivia HO, Reis-Cunha JL, Rodrigues-Luiz GF, Baptista RP, Baldeviano GC, Gerbasi RV, Dobson DE, Pratlong F, Bastien P, Lescano AG et al: Comparative genomic analysis of Leishmania (Viannia) peruviana and Leishmania (Viannia) braziliensis. BMC genomics 2015, 16:715.spa
dc.source.bibliographicCitationUrrea DA, Duitama J, Imamura H, Alzate JF, Gil J, Munoz N, Villa JA, Dujardin JC, Ramirez-Pineda JR, Triana-Chavez O: Genomic Analysis of Colombian Leishmania panamensis strains with different level of virulence. Scientific reports 2018, 8(1):17336.spa
dc.source.bibliographicCitationKuhls K, Mauricio IL, Pratlong F, Presber W, Schonian G: Analysis of ribosomal DNA internal transcribed spacer sequences of the Leishmania donovani complex. Microbes and infection 2005, 7(11-12):1224-1234.spa
dc.source.bibliographicCitationHerrera G, Hernandez C, Ayala MS, Florez C, Teheran AA, Ramirez JD: Evaluation of a Multilocus Sequence Typing (MLST) scheme for Leishmania (Viannia) braziliensis and Leishmania (Viannia) panamensis in Colombia. Parasites & vectors 2017, 10(1):236.spa
dc.source.bibliographicCitationBhattarai NR, Dujardin JC, Rijal S, De Doncker S, Boelaert M, Van der Auwera G: Development and evaluation of different PCR-based typing methods for discrimination of Leishmania donovani isolates from Nepal. Parasitology 2010, 137(6):947-957.spa
dc.source.bibliographicCitationOdiwuor S, Vuylsteke M, De Doncker S, Maes I, Mbuchi M, Dujardin JC, Van der Auwera G: Leishmania AFLP: paving the way towards improved molecular assays and markers of diversity. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2011, 11(5):960-967.spa
dc.source.bibliographicCitationPeacock CS, Seeger K, Harris D, Murphy L, Ruiz JC, Quail MA, Peters N, Adlem E, Tivey A, Aslett M et al: Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nature genetics 2007, 39(7):839- 847.spa
dc.source.bibliographicCitationZackay A, Cotton JA, Sanders M, Hailu A, Nasereddin A, Warburg A, Jaffe CL: Genome wide comparison of Ethiopian Leishmania donovani strains reveals differences potentially related to parasite survival. PLoS genetics 2018, 14(1):e1007133.spa
dc.source.bibliographicCitationRogers MB, Hilley JD, Dickens NJ, Wilkes J, Bates PA, Depledge DP, Harris D, Her Y, Herzyk P, Imamura H et al: Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome research 2011, 21(12):2129-2142.spa
dc.source.bibliographicCitationImamura H, Downing T, Van den Broeck F, Sanders MJ, Rijal S, Sundar S, Mannaert A, Vanaerschot M, Berg M, De Muylder G et al: Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent. eLife 2016, 5.spa
dc.source.bibliographicCitationLeprohon P, Fernandez-Prada C, Gazanion E, Monte-Neto R, Ouellette M: Drug resistance analysis by next generation sequencing in Leishmania. International journal for parasitology Drugs and drug resistance 2015, 5(1):26- 35.spa
dc.source.bibliographicCitationMukherjee A, Boisvert S, Monte-Neto RL, Coelho AC, Raymond F, Mukhopadhyay R, Corbeil J, Ouellette M: Telomeric gene deletion and intrachromosomal amplification in antimony-resistant Leishmania. Molecular microbiology 2013, 88(1):189-202.spa
dc.source.bibliographicCitationMonte-Neto R, Laffitte MC, Leprohon P, Reis P, Frezard F, Ouellette M: Intrachromosomal amplification, locus deletion and point mutation in the aquaglyceroporin AQP1 gene in antimony resistant Leishmania (Viannia) guyanensis. PLoS neglected tropical diseases 2015, 9(2):e0003476.spa
dc.source.bibliographicCitationFernandez-Prada C, Sharma M, Plourde M, Bresson E, Roy G, Leprohon P, Ouellette M: High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms. International journal for parasitology Drugs and drug resistance 2018, 8(2):165- 173.spa
dc.source.bibliographicCitationAshutosh, Sundar S, Goyal N: Molecular mechanisms of antimony resistance in Leishmania. Journal of medical microbiology 2007, 56(Pt 2):143-153.spa
dc.source.bibliographicCitationFrézard F, Monte-Neto R, Reis PG: Antimony transport mechanisms in resistant leishmania parasites. Biophysical Reviews 2014, 6(1):119-132.spa
dc.source.bibliographicCitationDumetz F, Cuypers B, Imamura H, Zander D, D'Haenens E, Maes I, Domagalska MA, Clos J, Dujardin JC, De Muylder G: Molecular Preadaptation to Antimony Resistance in Leishmania donovani on the Indian Subcontinent. mSphere 2018, 3(2).spa
dc.source.bibliographicCitationInbar E, Hughitt VK, Dillon LA, Ghosh K, El-Sayed NM, Sacks DL: The Transcriptome of Leishmania major Developmental Stages in Their Natural Sand Fly Vector. mBio 2017, 8(2).spa
dc.source.bibliographicCitationValdivia HO, Almeida LV, Roatt BM, Reis-Cunha JL, Pereira AA, Gontijo C, Fujiwara RT, Reis AB, Sanders MJ, Cotton JA et al: Comparative genomics of canine-isolated Leishmania (Leishmania) amazonensis from an endemic focus of visceral leishmaniasis in Governador Valadares, southeastern Brazil. Scientific reports 2017, 7:40804.spa
dc.source.bibliographicCitationReal F, Vidal RO, Carazzolle MF, Mondego JM, Costa GG, Herai RH, Wurtele M, de Carvalho LM, Carmona e Ferreira R, Mortara RA et al: The genome sequence of Leishmania (Leishmania) amazonensis: functional annotation and extended analysis of gene models. DNA research : an international journal for rapid publication of reports on genes and genomes 2013, 20(6):567-581.spa
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subjectLeishmaniaspa
dc.subjectResistenciaspa
dc.subjectADN-seqspa
dc.subjectARN-seqspa
dc.subjectGlucantimespa
dc.subjectSomiaspa
dc.subjectVNCspa
dc.subjectSNPsspa
dc.subject.ddcCiencias médicas, Medicinaspa
dc.subject.keywordLeishmaniasisspa
dc.subject.keywordDNA-seqspa
dc.subject.keywordRNA seqspa
dc.subject.keywordCNVspa
dc.subject.keywordSNPsspa
dc.subject.keywordResistancespa
dc.subject.lembMedicinaspa
dc.subject.lembEnfermedadesspa
dc.titleGenómica y transcriptómica comparativa en cepas de Leishmania de Colombiaspa
dc.title.TranslatedTitleGenomic and transcriptomic comparative in Leishmania species from Colombiaeng
dc.typedoctoralThesiseng
dc.type.documentTesisspa
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTesis de doctoradospa
local.department.reportEscuela de Medicina y Ciencias de la Saludspa
Archivos
Bloque original
Mostrando1 - 1 de 1
Cargando...
Miniatura
Nombre:
PatinoBlanco-LuzHelena-2019.pdf.pdf
Tamaño:
21.12 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento principal